ATE209216T1 - Cyclosporin-derivate mit anti-hiv-wirkung - Google Patents
Cyclosporin-derivate mit anti-hiv-wirkungInfo
- Publication number
- ATE209216T1 ATE209216T1 AT96927023T AT96927023T ATE209216T1 AT E209216 T1 ATE209216 T1 AT E209216T1 AT 96927023 T AT96927023 T AT 96927023T AT 96927023 T AT96927023 T AT 96927023T AT E209216 T1 ATE209216 T1 AT E209216T1
- Authority
- AT
- Austria
- Prior art keywords
- chain
- pct
- branched
- alkyl
- methyl
- Prior art date
Links
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title 1
- 230000036436 anti-hiv Effects 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 2
- 125000004423 acyloxy group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- -1 hydroxy, amino Chemical group 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 239000004474 valine Chemical group 0.000 abstract 2
- OKQFBOQZAAASNI-ZETCQYMHSA-N (2s)-4-acetyloxy-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)(C)OC(C)=O OKQFBOQZAAASNI-ZETCQYMHSA-N 0.000 abstract 1
- JRKMRRWEUORVRJ-YFKPBYRVSA-N (2s)-4-hydroxy-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)(C)O JRKMRRWEUORVRJ-YFKPBYRVSA-N 0.000 abstract 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 abstract 1
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 abstract 1
- 102000001189 Cyclic Peptides Human genes 0.000 abstract 1
- 108010069514 Cyclic Peptides Proteins 0.000 abstract 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 abstract 1
- 229930195711 D-Serine Natural products 0.000 abstract 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 abstract 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical group CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 abstract 1
- 150000008574 D-amino acids Chemical class 0.000 abstract 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical group CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Chemical group CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical group CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 abstract 1
- 239000004473 Threonine Chemical group 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Chemical group CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- XJODGRWDFZVTKW-ZCFIWIBFSA-N n-methylleucine Chemical compound CN[C@@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-ZCFIWIBFSA-N 0.000 abstract 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95111162 | 1995-07-17 | ||
| PCT/EP1996/003129 WO1997004005A2 (de) | 1995-07-17 | 1996-07-17 | Cyclosporin-derivate mit anti-hiv-wirkung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE209216T1 true ATE209216T1 (de) | 2001-12-15 |
Family
ID=8219438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96927023T ATE209216T1 (de) | 1995-07-17 | 1996-07-17 | Cyclosporin-derivate mit anti-hiv-wirkung |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5948884A (OSRAM) |
| EP (1) | EP0842191B1 (OSRAM) |
| JP (1) | JP3920919B2 (OSRAM) |
| KR (1) | KR100441220B1 (OSRAM) |
| CN (1) | CN1141317C (OSRAM) |
| AT (1) | ATE209216T1 (OSRAM) |
| AU (1) | AU722858B2 (OSRAM) |
| BR (1) | BR9609795A (OSRAM) |
| CA (1) | CA2226880C (OSRAM) |
| CZ (1) | CZ290754B6 (OSRAM) |
| DE (1) | DE59608274D1 (OSRAM) |
| HU (1) | HUP9900405A3 (OSRAM) |
| IL (1) | IL122754A (OSRAM) |
| NO (1) | NO980195D0 (OSRAM) |
| NZ (1) | NZ315324A (OSRAM) |
| PL (1) | PL324531A1 (OSRAM) |
| WO (1) | WO1997004005A2 (OSRAM) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2757521B1 (fr) * | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2757522B1 (fr) * | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2757520B1 (fr) * | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent |
| FR2762843B1 (fr) * | 1997-04-30 | 1999-12-10 | Rhone Poulenc Rorer Sa | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US6270957B1 (en) | 1997-08-26 | 2001-08-07 | Wisconsin Alumni Research Foundation | Non-Imuunosuppressive cyclosporins and their use in the prevention and treatment of HIV infection |
| US6316405B1 (en) * | 1997-08-26 | 2001-11-13 | Wisconsin Alumni Research Foundation | Cyclosporin a conjugates and uses therefor |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| FR2772768B1 (fr) * | 1997-12-19 | 2000-01-14 | Rhone Poulenc Rorer Sa | Nouveau procede de preparation de derives de cyclosporine |
| DE69912952T2 (de) | 1998-06-12 | 2004-09-02 | C-Chem Ag | Cyclosporine |
| AU759480B2 (en) * | 1998-07-01 | 2003-04-17 | Debiopharm S.A. | Novel cyclosporin with improved activity profile |
| KR100465012B1 (ko) * | 2001-05-11 | 2005-01-13 | 주식회사 엘지생활건강 | 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제 |
| US7141648B2 (en) | 2001-10-19 | 2006-11-28 | Isotechnika Inc. | Synthesis of cyclosporin analogs |
| US7108988B2 (en) | 2001-11-02 | 2006-09-19 | The J. David Gladstone Institutes | Methods of identifying agents for inhibiting lentivirus replication |
| US6987090B2 (en) * | 2002-05-09 | 2006-01-17 | Lg Household & Health Care Ltd. | Use of 3-position cyclosporin derivatives for hair growth |
| CA2518265A1 (en) * | 2003-03-17 | 2004-09-30 | Albany Molecular Research, Inc. | Novel cyclosporins |
| JP2008514702A (ja) * | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | 新規シクロスポリン類似体およびそれらの薬学的使用 |
| WO2006039163A2 (en) | 2004-09-29 | 2006-04-13 | Amr Technology, Inc. | Cyclosporin alkyne analogues and their pharmaceutical uses |
| US7196161B2 (en) * | 2004-10-01 | 2007-03-27 | Scynexis Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection |
| CA2583494C (en) * | 2004-10-01 | 2014-01-21 | Scynexis, Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection |
| WO2006041631A2 (en) * | 2004-10-06 | 2006-04-20 | Amr Technology, Inc. | Novel cyclosporin alkynes and their utility as pharmaceutical agents |
| KR20080059270A (ko) * | 2005-09-30 | 2008-06-26 | 싸이넥시스, 인크. | Ｃ형 간염 감염의 치료 및 예방을 위한 방법 및 제약조성물 |
| DE602006020152D1 (de) * | 2005-09-30 | 2011-03-31 | Scynexis Inc | Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion |
| US20070232532A1 (en) * | 2006-03-28 | 2007-10-04 | Amr Technology, Inc. | Use of cyclosporin alkene analogues for preventing or treating viral-induced disorders |
| US7696166B2 (en) * | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
| US7696165B2 (en) * | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
| CN101511357B (zh) | 2006-05-19 | 2011-11-02 | 西尼克斯公司 | 环孢菌素类化合物及其组合物在制备治疗和预防眼部疾病的药物中的应用 |
| EP2027761A1 (fr) * | 2006-06-02 | 2009-02-25 | Claude Annie Perrichon | Gestion des electrons actifs |
| WO2008069917A2 (en) | 2006-11-20 | 2008-06-12 | Scynexis, Inc. | Novel cyclic peptides |
| WO2008127613A1 (en) * | 2007-04-11 | 2008-10-23 | Scynexis, Inc. | New pharmaceutical compositions |
| US9090671B2 (en) * | 2008-06-06 | 2015-07-28 | Scynexis, Inc. | Macrocyclic peptides |
| US20090306033A1 (en) * | 2008-06-06 | 2009-12-10 | Keqiang Li | Novel cyclic peptides |
| DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
| CA2748389A1 (en) * | 2008-12-31 | 2010-07-08 | Scynexis, Inc. | Derivatives of cyclosporin a |
| CN101874902B (zh) * | 2009-06-19 | 2013-04-03 | 清华大学 | 一种用于人工椎间盘髓核假体材料的制备方法 |
| AU2010339460A1 (en) * | 2009-12-30 | 2012-07-19 | Scynexis Inc. | Cyclosporine analogues |
| US9573978B2 (en) | 2010-08-12 | 2017-02-21 | S&T Global, Inc. | Cyclosporin derivatives for the treatment and prevention of a viral infection |
| WO2012075494A1 (en) * | 2010-12-03 | 2012-06-07 | S&T Global Inc. | Novel cyclosporin derivatives for the treatment and prevention of a viral infection |
| US9890198B2 (en) | 2010-12-03 | 2018-02-13 | S&T Global Inc. | Cyclosporin derivatives and uses thereof |
| KR102011339B1 (ko) | 2010-12-15 | 2019-08-16 | 콘트라빌 파마슈티컬스, 인코퍼레이티드 | 아미노산 1 및 3에서 변형된 사이클로스포린 유사체 분자 |
| EP2705856A1 (en) | 2012-09-07 | 2014-03-12 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. | Compounds for the treatment of neurodegenerative disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0194972B1 (en) * | 1985-03-11 | 1992-07-29 | Sandoz Ag | Novel cyclosporins |
| US5122511A (en) * | 1990-02-27 | 1992-06-16 | Merck & Co., Inc. | Immunosuppressive cyclosporin analogs with modified amino acids at position-8 |
| DK0484281T4 (da) * | 1990-11-02 | 2001-02-05 | Novartis Ag | Cyclosporiner |
-
1996
- 1996-07-17 CN CNB96196264XA patent/CN1141317C/zh not_active Expired - Fee Related
- 1996-07-17 PL PL96324531A patent/PL324531A1/xx unknown
- 1996-07-17 AU AU67001/96A patent/AU722858B2/en not_active Ceased
- 1996-07-17 IL IL12275496A patent/IL122754A/en not_active IP Right Cessation
- 1996-07-17 HU HU9900405A patent/HUP9900405A3/hu unknown
- 1996-07-17 US US08/009,815 patent/US5948884A/en not_active Expired - Lifetime
- 1996-07-17 WO PCT/EP1996/003129 patent/WO1997004005A2/de not_active Ceased
- 1996-07-17 CA CA002226880A patent/CA2226880C/en not_active Expired - Fee Related
- 1996-07-17 CZ CZ199851A patent/CZ290754B6/cs not_active IP Right Cessation
- 1996-07-17 DE DE59608274T patent/DE59608274D1/de not_active Expired - Lifetime
- 1996-07-17 JP JP50628797A patent/JP3920919B2/ja not_active Expired - Fee Related
- 1996-07-17 EP EP96927023A patent/EP0842191B1/de not_active Expired - Lifetime
- 1996-07-17 KR KR10-1998-0700269A patent/KR100441220B1/ko not_active Expired - Fee Related
- 1996-07-17 AT AT96927023T patent/ATE209216T1/de not_active IP Right Cessation
- 1996-07-17 BR BR9609795A patent/BR9609795A/pt not_active Application Discontinuation
- 1996-07-17 NZ NZ315324A patent/NZ315324A/en not_active IP Right Cessation
-
1998
- 1998-01-15 NO NO980195A patent/NO980195D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1192750A (zh) | 1998-09-09 |
| CN1141317C (zh) | 2004-03-10 |
| CZ290754B6 (cs) | 2002-10-16 |
| CA2226880A1 (en) | 1997-02-06 |
| AU6700196A (en) | 1997-02-18 |
| NO980195L (no) | 1998-01-15 |
| CZ5198A3 (cs) | 1998-04-15 |
| US5948884A (en) | 1999-09-07 |
| IL122754A (en) | 2001-10-31 |
| WO1997004005A2 (de) | 1997-02-06 |
| HUP9900405A2 (hu) | 1999-06-28 |
| MX9800477A (es) | 1998-09-30 |
| JP3920919B2 (ja) | 2007-05-30 |
| JP2000502320A (ja) | 2000-02-29 |
| CA2226880C (en) | 2007-04-10 |
| WO1997004005A3 (de) | 1997-02-27 |
| IL122754A0 (en) | 1998-08-16 |
| AU722858B2 (en) | 2000-08-10 |
| KR100441220B1 (ko) | 2005-02-24 |
| BR9609795A (pt) | 1999-03-16 |
| DE59608274D1 (de) | 2002-01-03 |
| EP0842191B1 (de) | 2001-11-21 |
| EP0842191A2 (de) | 1998-05-20 |
| NO980195D0 (no) | 1998-01-15 |
| HUP9900405A3 (en) | 2001-04-28 |
| PL324531A1 (en) | 1998-06-08 |
| NZ315324A (en) | 1999-10-28 |
| KR19990028967A (ko) | 1999-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE209216T1 (de) | Cyclosporin-derivate mit anti-hiv-wirkung | |
| DE60119145D1 (de) | Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzung | |
| KR960703015A (ko) | 후천성 면역결핍증 치료용 약물의 제조시 노나- 및 데카펩타이드의 용도(Use of nona-and decapeptides in the preparation of a durg for the treatment of AIDS) | |
| HUP0100100A2 (hu) | Hepatitis C inhibitor peptid-analógok, ezeket hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| ATE267211T1 (de) | Impfstoff gegen hpv | |
| FR2762843B1 (fr) | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent | |
| ATE144143T1 (de) | Künstlicher impfstoff gegen aids-virus | |
| DK1278534T3 (da) | Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1 | |
| ES2100240T3 (es) | Bacteriofagos modificados mediante ingenieria genetica y vacunas que los contienen. | |
| ATE422362T1 (de) | Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose | |
| CA2042236A1 (en) | Seroreactive epitopes on proteins of human papillomavirus (hpv) 18 | |
| ATE130198T1 (de) | Herstellung eines virus und reinigung von virenüberzugsproteinen zur impfstoffverwendung. | |
| DE69828801D1 (de) | Peptide abgeleitet vom bindungs (g) protein des respiratorisches synzytialvirus | |
| DE3261304D1 (en) | Retro-inverso analogues of c-terminal penta and hexapeptides of substance p. | |
| ATE177843T1 (de) | Peptomere mit erhöhter immunogenizität | |
| WO1999051256A3 (en) | Use of l-glu-l-trp in the treatment of hiv infection | |
| ES2095899T3 (es) | Peptidos de la proteina gag de vih, su preparacion y uso. | |
| WO1994004565A3 (en) | Ipnv vaccine | |
| SE9501512D0 (sv) | Synthetic peptide-defined eptopes useful for vaccination against papillomavirus | |
| ATE349532T1 (de) | Zytotoxisches t-zellepitop des papillomavirus l1- proteins und seine verwendung in diagnostik und therapie | |
| RU94042882A (ru) | Препарат с иммуностимулирующей активностью |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REN | Ceased due to non-payment of the annual fee |